Why PFE or another putative suitor will pay top dollar for ARIA....
Thank you, Kinghana...this type of analysis is important for valuation of ARIA as to any potential acquirer of it....So, if they can clear 60M in Aus...over $1B annually if you add on the EU and the USA is not out of the question...
Some rough back of the envelope stuff:
1 The population of Australia is estimated to be 23,364,244 as of 30 January 2014
2 The European Union presently consists of 28 countries and has a total population of just over 500 million citizens (504,456,000).
3 Census Bureau Projects U.S. Population of 317.3 Million on New Year's Day ... 2014
So from the above the populations of the EU and the USA are 35.17 X that of the population of Aus..
So, take that 1500 number and multiply it by 35.17X.
This gives you 52,785 imputed patients in the US and the EU..
$60M x 35.17....
This gives 2,110,200,000...or,
Over $2.1B in revenue...
Just to be conservative knock this down to $1.4B annually in revenue..
Next, ARIA has Shares Outstanding of 185.66M
Now assume a 35% net profit margin on $1.4B...this gives 490,000,000 or 490M
490M/185.66M shares out..
Gives $2.63 eps...put just a 15X multiple on this sum...gives a projected ARIA share price of $39.58...with sales ww in the EU, NA and Aus...Note that SA, RSA and Japan are NOT included
Believe me...PFE will pay top dollar for ARIA...this drug could generate huge ww annual sales..and Berger knows whats what and will not sell on the cheap...other opinions welcome... Less
viel glück und viel segen auf all meinen wegen;)